Wed, March 28, 2012
Tue, March 27, 2012
Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
Wed, March 21, 2012
Tue, March 20, 2012
Mon, March 19, 2012
Sun, March 18, 2012
Fri, March 16, 2012
Thu, March 15, 2012
Wed, March 14, 2012

Isis Pharmaceuticals Hosts Dr. Raul Santos to Review KYNAMROa" Data That Will Have Been Presented at ISA 2012 - XVI Internation


//health-fitness.news-articles.net/content/2012/ .. -been-presented-at-isa-2012-xvi-internation.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Webcast Alert: Isis Pharmaceuticals Hosts Dr. Raul Santos to Review KYNAMRO? Data... -- CARLSBAD, Calif., March 22, 2012 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals Hosts Dr. Raul Santos to Review KYNAMRO? Data That Will Have Been Presented at ISA 2012 - XVI International Symposium on Atherosclerosis

[ ]

CARLSBAD, Calif., March 22, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]) announces the following webcast:

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

What:

Data from KYNAMRO Long-Term Extension Study presented at ISA 2012 - XVI International Symposium on Atherosclerosis

 

 

When:

Thursday, March 29th at 4:00 p.m. ET / 1:00 p.m. PT

 

 

Where:

[ www.isispharm.com ]

 

 

How:

Live on the Internet.  Simply log onto our Web site listed above.

 

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources